Rafutrombopag
As of the edition of 20 October 2026, Rafutrombopag is a small molecule: stopped in 2025; acts on MPL.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Small molecule
- Registered trials
- 24, 2 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Digestive system; Inherited and neonatal; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MPL | Thrombopoietin receptor | P40238 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 4 | 1 | 1 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 10 | 1 | 3 | 0 |
| Phase 3 | 6 | 2 | 1 | 2 |
| Phase 4 | 1 | 0 | 0 | 0 |
| All trials | 24 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jiangsu HengRui Medicine | Lead sponsor of trials | 2019 to now |
| Atridia | Lead sponsor of trials | 2021 to now |